Fingolimod Therapy for Multiple Sclerosis

Abstract

Because of its potent efficacy and oral route of administration, the approval of fingolimod as treatment for relapsing-remitting multiple sclerosis (MS) was highly anticipated. The therapeutic and adverse effects are mediated by modulation of sphingosine 1-phosphate receptors. Fingolimod inhibits the egress of lymphocytes from lymph nodes and may also have direct effects on the central nervous system. The clinical trials that led to the approval of fingolimod demonstrated benefit on relapses, disability progression, magnetic resonance imaging (MRI) activity, and brain volume loss in treatment-naïve and previously treated patients with relapsing-remitting MS. The use of fingolimod in clinical practice has been limited by concerns for cardiac effects, infection, and macular edema as well as the relative lack of long-term safety data for this drug with a novel mechanism of action. Additional clinical trial and postmarketing data suggest that fingolimod is a safe, effective, and well-tolerated treatment option when patients are selected and monitored appropriately.

Keywords

multiple sclerosis - therapy - fingolimod - sphingosine 1-phosphate

• References

• 1 Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010; 33 (2) 91-101
• 2 Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011; 69 (5) 759-777
• 3 Mehling M, Johnson TA, Antel J, Kappos L, Bar-Or A. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology 2011; 76 (8) (Suppl. 03) S20-S27
• 4 Mehling MKL, Kappos L, Derfuss T. Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions. Curr Neurol Neurosci Rep 2011; 11 (5) 492-497
• 5 Gräler MHGE, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 2004; 18 (3) 551-553
• 6 Mehling MBV, Brinkmann V, Antel J , et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008; 71 (16) 1261-1267
• 7 Brinkmann V, Billich A, Baumruker T , et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010; 9 (11) 883-897
• 8 Dev KK, Mullershausen F, Mattes H , et al. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther 2008; 117 (1) 77-93
• 9 Foster CA, Howard LM, Schweitzer A , et al. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 2007; 323 (2) 469-475
• 10 Miron VE, Schubart A, Antel JP. Central nervous system-directed effects of FTY720 (fingolimod). J Neurol Sci 2008; 274 (1-2) 13-17
• 11 Coelho RP, Payne SG, Bittman R, Spiegel S, Sato-Bigbee C. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther 2007; 323 (2) 626-635
• 12 Kovarik JM, Hartmann S, Bartlett M , et al. Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects. Biopharm Drug Dispos 2007; 28 (2) 97-104
• 13 Kovarik JM, Schmouder R, Barilla D, Wang Y, Kraus G. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. Br J Clin Pharmacol 2004; 57 (5) 586-591
• 14 Warnke C, Stüve O, Hartung HP, Fogdell-Hahn A, Kieseier BC. Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat 2011; 7: 519-527
• 15 Kappos L, Antel J, Comi G , et al; FTY720 D2201 Study Group. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355 (11) 1124-1140
• 16 Kappos L, Radue EW, O'Connor P , et al; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362 (5) 387-401
• 17 Cohen JA, Barkhof F, Comi G , et al; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362 (5) 402-415
• 18 Kappos L, Radue E-W, O' Connor P , et al. Long-term efficacy and safety of fingolimod (FTY720) in relapsing-remitting multiple sclerosis (RRMS): results from the extension of the phase III FREEDOMS study. Paper presented at: Annual Meeting of the American Academy of Neurology; April 26, 2012; New Orleans, LA
• 19 Antel J, Montalban X, O'Connor P , et al. Long-term (7-year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Paper presented at: Annual Meeting of the American Academy of Neurology; April 23, 2012; New Orleans, LA
• 20 Johnson TA, Shames I, Keezer M , et al. Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients. Clin Immunol 2010; 137 (1) 15-20
• 21 U.S. Food and Drug Administration. (FDA) Center for Drug Evaluation and Research (CDER). Fingolimod Background Package (NDA 22–257). Available at: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/peripheralandcentralnervoussystemdrugsadvisorycommittee/ucm216553.pdf . Accessed May 6, 2012
• 22 Collins W, Cohen J, O' Connor P , et al. Long-term safety of oral fingolimod (FTY720) in relapsing multiple sclerosis: integrated analyses of phase 1 and phase 3 studies (P843). Mult Scler 2010; 16 (Suppl. 10) S295
• 23 Schmouder R, Serra D, Wang Y , et al. FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. J Clin Pharmacol 2006; 46 (8) 895-904
• 24 DiMarco JP, O'Connor P, Cohen JA , et al. First-dose effect of fingolimod: pooled safety data from two phase 3 studies (TRANSFORMS and FREEDOMS). Mult Scler 2010; 16 (Suppl. 10) S290
• 25 Espinosa PS, Berger JR. Delayed fingolimod-associated asystole. Mult Scler 2011; 17 (11) 1387-1389
• 26 U.S. Food and Drug Administration. FDA Drug Safety Communication: Safety Review of a Reported Death after the First Dose of Multiple Sclerosis Drug Gilenya (Fingolimod). Available at: http://www.fda.gov/Drugs/DrugSafety/ucm284240.htm . Accessed May 6, 2012
• 27 Salvadori M, Budde K, Charpentier B , et al; FTY720 0124 Study Group. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant 2006; 6 (12) 2912-2921
• 28 Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology 2012; 78 (9) 672-680
• 29 U.S. Food and Drug Administration. FDA Approved Labeling Text for GILENYA (Fingolimod) Capsules (NDA 02257). Updated April 2012. Washington, DC: U.S. Food and Drug Administration;
• 30 ONE Neuro-Ophthalmology Committee. Oral MS Drug May Increase Risk for Macular Edema: A Report from the North American Neuro-Ophthalmology Society (NANOS) and the AAO. Released September 10, 2011. Available at: http://www.nanosweb.org/files/public/MS_drug_may_increase_risk_for_RVO1NOTRACK2lf.pdf . Accessed May 6, 2012
• 31 Novartis. Gilenya (Finglimod) Safety Information Update (Released April 13, 2012). Available at: http://www.novartis.com/downloads/newsroom/product-related-info-center/statement-PML.pdf . Accessed May 15, 2012
• 32 Francis GS, Kappos L, O' Connor P , et al. Lymphocytes and fingolimod–temporal pattern and relationship with infections. Mult Scler 2010; 16 (Suppl 10) S146
• 33 Ontaneda D, Cohen JA. Potential mechanisms of efficacy and adverse effects in the use of fingolimod (FTY720). Expert Rev Clin Pharmacol 2011; 4 (5) 567-570
• 34 Schwarz A, Korporal M, Hosch W, Max R, Wildemann B. Critical vasospasm during fingolimod (FTY720) treatment in a patient with multiple sclerosis. Neurology 2010; 74 (24) 2022-2024
• 35 Pfaff M, Powaga N, Akinci S , et al. Activation of the SPHK/S1P signalling pathway is coupled to muscarinic receptor-dependent regulation of peripheral airways. Respir Res 2005; 6: 48
• 36 Brinkmann V, Baumruker T. Pulmonary and vascular pharmacology of sphingosine 1-phosphate. Curr Opin Pharmacol 2006; 6 (3) 244-250
• 37 Collins W, Francis G, Koren G , et al. Lack of interaction between fingolimod (FTY720) and oral contraceptives, and pregnancy experience in the clinical program of fingolimod in multiple sclerosis. Paper presented at: Annual Meeting of the American Academy of Neurology; April 9, 2011; Honolulu, HI
• 38 Castrop F, Kowarik MC, Albrecht H , et al. Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?. Neurology 2012; 78 (12) 928-930
• 39 Min J-H, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 2012; 18 (1) 113-115
• 40 Havla JB, Pellkofer HL, Meinl I, Gerdes LA, Hohlfeld R, Kümpfel T. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. Arch Neurol 2012; 69 (2) 262-264
• 41 Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med 2012; 366 (4) 339-347
• 42 Novartis. FTY720 in Patients With Primary Progressive Multiple Sclerosis. ClinicalTrials.gov Identifier: NCT00731692. Available at: http://ClinicalTrials.gov/show/NCT00731692 . Accessed May 15, 2012
• 43 Novartis. Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod. ClinicalTrials.gov Identifier: NCT01499667. Available at: http://ClinicalTrials.gov/show/NCT01499667 . Accessed May 15, 2012
• 44 GlaxoSmithKline. A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-Phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers. ClinicalTrials.gov Identifier: NCT01466322. Available at: http://ClinicalTrials.gov/show/NCT01466322 . Accessed May 15, 2012
• 45 Novartis. Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-Remitting Multiple Sclerosis. ClinicalTrials.gov Identifier: NCT00879658. Available at: http://ClinicalTrials.gov/show/NCT00879658 . Accessed May 15, 2012
• 46 Ono Pharma A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis. ClinicalTrials.gov Identifier: NCT01081782. Available at: http://ClinicalTrials.gov/show/NCT01081782 . Accessed May 15, 2012